top of page
September 1, 2022 ​ Adecto Pharmaceuticals awarded Phase II NCI SBIR grant to continue development of an ADAM8 cancer diagnostic
August 11, 2020 ​ Adecto Pharmaceuticals president Dr. Gail Sonenshein receives Tufts University School of Medicine 2020 Zucker Award for outstanding career achievements in women's health research
May 24, 2019 ​ Adecto Pharmaceuticals awarded Phase I NCI SBIR grant for development of ADAM8 cancer diagnostic
October 22, 2018 ​ Adecto Pharmaceuticals awarded multimillion-dollar NCI SBIR grant to continue development of ADAM8 targeted therapy
March 1, 2018 ​ Adecto Pharmaceuticals selected to participate in MassBio’s MassCONNECT mentoring program
April 2, 2017 ​ Adecto Pharmaceuticals presents poster on selection of lead candidate therapeutic antibodies at the 2017 AACR annual meeting
April 15, 2016 ​ Adecto Pharmaceuticals awarded Phase I NCI STTR grant for the development of ADAM8 targeted therapies
April 13, 2015 ​ Adecto Pharmaceuticals wins Tufts $100K New Ventures Competition
March 18, 2014 ​ New Hope for Tough-to-Treat Breast Cancers Tufts researchers find promising target in battle against aggressive tumors
bottom of page
